New Sitomet

Sitomet® is a combination of two anti-hyperglycemic agents-Sitagliptin Phosphate Monohydrate and Metformin Hydrochloride with complementary mechanisms of action to improve glycemic control in patients with type 2 diabetes. Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which exerts its action by slowing the inactivation of incretin hormones. Incretin hormones, including glucagon-like peptide-1(GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), are released by the intestine throughout the day and levels are increased in response to a meal. These hormones are rapidly inactivated by the enzyme, DPP-4. The incretins are part of an endogenous system involved in the physiologic regulation of glucose homeostasis. When blood glucose concentrations are normal or elevated, GLP-1 and GIP increase insulin synthesis and release from pancreatic beta cells by intracellular signaling pathways involving cyclic AMP. GLP-1 also lowers glucagon secretion from pancreatic alpha cells, leading to reduced hepatic glucose production. Metformin Hydrochloride is a member of biguanide class. The pharmacologic mechanism of action of Metformin is different from other classes of oral anti-hyperglycemic agents. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and increases peripheral glucose uptake and utilization. 


  • Product Code: BMS123
  • Availability: In Stock
  • BDT 180.00

Tags: Sitomet